法國(guó)生物梅里埃bioMérieux   www.biomerieux.com.cn  www.biomerieux.com   www.merieux-alliance.com
生物梅里埃公司創(chuàng)建於1963年，公司依賴自身的科技研究和工業(yè)生產(chǎn)資源，始終致力於開發(fā)作為醫(yī)療和工業(yè)用途的體外診斷產(chǎn)品。 集團(tuán)專門設(shè)計(jì)、開發(fā)、生產(chǎn)和推廣應(yīng)用在臨床和工業(yè)的系統(tǒng)。生物梅里埃的診斷系統(tǒng)是由試劑、 儀器和軟件組成，主要是為傳染病、工業(yè)微生物控制、心血管病和腫瘤病等四個(gè)主要策略性領(lǐng)域來設(shè)計(jì)。
在2006年，公司銷售額為10億3千7百萬歐元，集團(tuán)共有11個(gè)生產(chǎn)基地和9個(gè)研究中心，分布于歐洲、北美洲和南美洲。集團(tuán)全球擁有35個(gè)辦事處，至2005年12月31日集團(tuán)員工超過5,500人。
生物梅里埃公司產(chǎn)品有兩個(gè)應(yīng)用領(lǐng)域 : 臨床和工業(yè)，臨床市場(chǎng)占總銷售額的86.2%，而工業(yè)市場(chǎng)占13.8%。工業(yè)的應(yīng)用主要在食品、藥品和化妝品的微生物分析，增長(zhǎng)非常迅速，生物梅里埃是全球體外診斷領(lǐng)域的第八大生產(chǎn)商。
生物梅里埃中國(guó)有限公司已經(jīng)20年的發(fā)展，自動(dòng)化微生物鑒定分析系統(tǒng)的用戶已達(dá)1400余家，自動(dòng)微生物培養(yǎng)系統(tǒng)已達(dá)700余家，全自動(dòng)細(xì)菌計(jì)數(shù)系統(tǒng)60余臺(tái)，手工產(chǎn)品用戶覆蓋全國(guó)的省市70%以上。同時(shí)公司擁有數(shù)十名微生物臨床及工業(yè)領(lǐng)域?qū)I(yè)人員和工程技術(shù)人員，其中許多人員都來自檢驗(yàn)一線，擁有豐富的檢驗(yàn)經(jīng)驗(yàn)和儀器維修經(jīng)驗(yàn)。全面負(fù)責(zé)生物梅里埃公司產(chǎn)品的銷售，儀器的安裝、維護(hù)及保養(yǎng)，以及用戶的培訓(xùn)及技術(shù)支持。
生物梅里埃公司擁有完善的產(chǎn)品策略、銷售策略和市場(chǎng)發(fā)展策略以全面的技術(shù)支持作後盾，為用戶提供感染病檢測(cè)產(chǎn)品及“全面解決問題”的服務(wù)是生物梅里埃公司的宗旨。相信會(huì)為您提供不斷完善的產(chǎn)品和令您滿意的服務(wù)。

技術(shù)熱線：400-630-8137
培訓(xùn)中心電話：021-60978335
傳真：021-60978399

生物梅里埃辦事處
1. 梅里埃診斷產(chǎn)品(上海)有限公司
中國(guó)上海市浦東新區(qū)康橋工業(yè)區(qū)浦三路4633號(hào)
郵編:201315
電話:(86-21) 6097 8388
傳真:(86-21) 6097 8399
 
2. 生物梅里埃香港辦事處
中國(guó)香港九龍長(zhǎng)沙灣長(zhǎng)裕街8號(hào)億京廣場(chǎng)19樓
電話: (852) 2356 7033
傳真: (852) 2330 2085
 
3. 生物梅里埃北京辦事處
中國(guó)北京市朝陽區(qū)建國(guó)門外大街甲24號(hào)東海中心1601室
郵政編碼：100004
電話: (86-10) 65156963
傳真: (86-10) 65156993
 
4. 生物梅里埃華南及西南辦事處 (廣州辦事處)
中國(guó)廣州環(huán)巿東路371-375號(hào)世界貿(mào)易中心大廈南塔2605室
郵政編碼：510095
電話: (86-20)87627010
傳真: (86-20)87627015
 
5.生物梅里埃華南及西南辦事處 (成都辦事處)
成都市人民南路一段86號(hào)城市之心大廈16樓A、N單元
郵政編碼：610016
電話：(86-28)-8620 2052
傳真：(86-28) 8620 2051
 
6.生物梅里埃臺(tái)灣辦事處
臺(tái)北市松山區(qū)南京東路5段34號(hào)4樓
電話: (886-2)2528 5180
傳真: (886-2)2528 5233
 

 bioMérieux’s mission is to contribute to the improvement of public health worldwide through in vitro diagnostics. Throughout its history, our company has committed to four priorities, which today, represent its strength:
Our independence and expertise in the field of in vitro diagnostics allow us to respond rapidly in today’s complex environment and to form partnerships that are vital to our scientific and international growth. 

Our international scope, with 84% of sales coming from outside of France. Established in 150 countries, with 39 subsidiaries and an extensive network of distributors, we are close to our customers, wherever they may be, and provide a line of products tailored to the realities of each region. 

45 years of experience and know-how in the field of infectious diseases allows bioMérieux, a world leader in microbiology, to respond to major public health issues, and affirm its position as a key player in clinical diagnostics and industrial microbiological quality control. 

Scientific and technological innovation is at the heart of the bioMérieux strategy. It has enabled us to extend our expertise to the fields of cancer and cardiovascular diseases, complementing that of infectious diseases. bioMérieux dedicates considerable resources to R&D (over 12% of its sales), pursuing an ambitious policy based on multidisciplinary internal teams and a network of international partnerships and scientific affiliations. 
bioMérieux is part of the Mérieux Alliance group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.
bioMérieux is committed to serving a medicine that is continually more reactive, preventive and personalized in order to improve the quality of patient care. This is why our teams are located all over the world. They are at work developing diagnostic systems and reagents that respond perfectly to the demands of physicians and biologists, while anticipating scientific and technological developments. We also rely on the support of our shareholders, partners in our development, who through their continued confidence, allow us to envision the diagnostics of tomorrow.